TY - JOUR
T1 - IgG4 related autoimmune pancreatitis
T2 - An overview and the emerging role of serum eotaxin as a potential treatment target
AU - Mari, Amir
AU - Kadah, Anas
AU - Mahamid, Mahmud
AU - Sbeit, Wisam
AU - Khoury, Tawfik
N1 - Publisher Copyright:
© 2019 Israel Medical Association. All rights reserved.
PY - 2019/9
Y1 - 2019/9
N2 - Autoimmune pancreatitis (AIP) is a rare disease that has been classified into two subtypes. Type 1 is believed to be mediated by immunoglobulin G4 (IgG4) and type 2 is related to granulocytic epithelial lesions, but the pathogenetic mechanisms in both are still unknown. The patho-mechanism of AIP type 1 is suggested to be secondary to autoimmunity or allergy due to the increased serum IgG4 and immunoglobulin E levels, abundant infiltration of IgG4, plasmacytes and lymphocytes in the pancreas, and fibrosis. Both types of AIP respond to steroid treatment. The relapse rate after remission is high and reaches 30-50% within 6-12 months in AIP type 1; however, in AIP type 2 relapse is rare. The maintenance therapy and therapeutic strategy for relapsing patients with type 1 is managed with low dose steroids, however there are no consensus guidelines. In this review we discuss the current understanding of AIP, highlighting the emerging potential role of eotaxin in pathogenesis, classification, and management of the disease.
AB - Autoimmune pancreatitis (AIP) is a rare disease that has been classified into two subtypes. Type 1 is believed to be mediated by immunoglobulin G4 (IgG4) and type 2 is related to granulocytic epithelial lesions, but the pathogenetic mechanisms in both are still unknown. The patho-mechanism of AIP type 1 is suggested to be secondary to autoimmunity or allergy due to the increased serum IgG4 and immunoglobulin E levels, abundant infiltration of IgG4, plasmacytes and lymphocytes in the pancreas, and fibrosis. Both types of AIP respond to steroid treatment. The relapse rate after remission is high and reaches 30-50% within 6-12 months in AIP type 1; however, in AIP type 2 relapse is rare. The maintenance therapy and therapeutic strategy for relapsing patients with type 1 is managed with low dose steroids, however there are no consensus guidelines. In this review we discuss the current understanding of AIP, highlighting the emerging potential role of eotaxin in pathogenesis, classification, and management of the disease.
KW - Autoimmune pancreatitis (AIP)
KW - Eotaxin
KW - Immunoglobulin G4-related disease
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=85072579829&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 31542909
AN - SCOPUS:85072579829
SN - 1565-1088
VL - 21
SP - 620
EP - 623
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 9
ER -